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Edited by Gerrit van MeerAbstract The ABC transporter LmrA in Lactococcus lactis
confers resistance to a wide range of antibiotics and cytotoxic
drugs and is a functional homologue of P-glycoprotein. Recently,
solid-state NMR methods have shown potential for structural-
and non-perturbing, site directed functional studies. These
experiments require isotopic labelling of selected sites. We have
developed a strategy to produce large quantities of selectively
labelled LmrA reconstituted at a high density in lipid mem-
branes. This makes the 64 kDa integral membrane protein LmrA
and therefore the ABC transporter superfamily accessible to
NMR analysis.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The phenomenon of multidrug resistance, by which cells
become resistant to structurally and functionally diverse
pharmaceuticals, is often caused by active drug extrusion from
the cell by primary-active or secondary-active transporters.
Primary-active transporters such as P-glycoprotein, BCRP and
MRP1 use ATP hydrolysis and are ubiquitous in prokaryotic
and eukaryotic organisms. One member of this ATP-binding
cassette (ABC) family is the Lactococcus lactis multidrug
resistance protein LmrA, which can functionally substitute for
P-glycoprotein in lung ﬁbroblast cells [1]. LmrA is a 590 amino
acid polypeptide with six transmembrane spannning segments
in the N-terminal hydrophobic domain and a C-terminal
hydrophilic nucleotide-binding domain (NBD). The protein is
thought to function as a homodimer as suggested by the
negative dominance of an inactive mutant over an active
wildtype LmrA protein in a co-reconstituted liposomal system.
Furthermore, covalent fusion of two wildtype LmrA mono-
mers yields a functional transporter [2]. LmrA provides a po-
tentially accessible system for advanced biophysical studies,
since ampliﬁed expression at high levels has been previously* Corresponding author. Fax: +49-69798-29929.
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doi:10.1016/j.febslet.2004.05.016demonstrated [3]. The ﬁrst structural and dynamic studies on
LmrA were carried out by ATR-FTIR and 1H/2H exchange
experiments providing evidence for transmembrane oriented
a-helices [4] as well as for long-range conformational changes
during the transport cycle [5]. Indication of the existence of an
aqueous chamber formed by the transmembrane segments
open to the intracellular space in the non-energized state was
found by cysteine scanning accessibility studies [6].
So far, no three-dimensional (3D) structure has been re-
ported for full-length LmrA. However, a number of high res-
olution structures for other members of the ABC family have
been obtained recently. The structure ofEscherichia coli BtuCD
[7], a vitamin B12 transporter, has been determined at 3.2 A
resolution. A 4.5 A resolution structure has been reported for
E. coli MsbA [8], a lipid A transporter [9] that has overlapping
substrate speciﬁcity with LmrA [10]. The BtuCD structure has
been proposed to be a framework for ABC transporter archi-
tecture [7] but interestingly has a somewhat diﬀerent subunit
arrangement compared to MsbA. BtuCD has the two mem-
brane spanning subunits and the two NBDs in close contact
with each other allowing ATP binding at the NBD:NBD in-
terface. The structure of dimeric MsbA reveals that the NBD
dimer occurs away from the dimer interface. The low resolution
structure of YvcC, a homologue of MsbA and LmrA from
B. subtilis [11] and L. lactis, is in agreement with the MsbA
crystal structure and supports the existence of a central open
chamber between the two subunits forming the homodimer.
The diﬀerences between the structures of these ABC trans-
porters may imply that alternative mechanisms of ATP de-
pendent drug transport exist within the ABC transporter
superfamily.
In addition to structures of whole transporters, crystal
structures of NBDs crystallised in isolation from the trans-
membrane domains of the transporter may also shed light on
potential transport and energy coupling mechanisms. For
example, the crystal structure of MalK, a dimer of NBDs that
form part of the E. coli maltose transporter when in complex
with the two membrane spanning subunits MalG and MalF,
has been determined. Its ATP bound and ATP free form shows
a closed and an open structure [12] which, in complex with
MalG and MalF, could represent a ‘‘tweezer-like’’ mechanism
for transfer of ATPase activity. This mechanism would be
diﬃcult to reconcile with the MsbA and YvcC structures if,ation of European Biochemical Societies.
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Recent electron diﬀraction structures of P-glycoprotein in both
the ground and ATP bound states have provided hints about
the way transmembrane domains alter conformation upon
nucleotide binding and about the possibilities that hydropho-
bic drugs could enter the protein from the lipid bilayer [13].
Unfortunately, the NBDs are poorly resolved and do not oﬀer
a conclusive model for the nature of the subunit assembly and
for the coupling of ATP binding in one domain to confor-
mational changes in another.
Structural studies on ABC transporters rely on the avail-
ability of well diﬀracting 2D or 3D crystals. Meanwhile, NMR
and EPR approaches can provide site-speciﬁc information on
substrate–protein interactions, conformational changes and
dynamics. Furthermore, solid-state NMR, which does not rely
on fast molecular tumbling, allows studies in a native-like
environment and has been increasingly applied to membrane
proteins [14–16].
NMR on macroscopically aligned samples, as demonstrated
by PISEMA experiments [17], can provide structural infor-
mation via orientation constraints and resonance assignments.
Similar methods were also used to determine the orientation of
myristoylated recoverin, a soluble protein that attaches to lipid
bilayers in the presence of high Ca2þ concentration [18]. The
prospects of applying this approach to larger membrane pro-
teins have been theoretically analysed [19] and also practically
demonstrated with speciﬁcally 15N-labelled purple membrane
[20]. A more universal approach to larger membrane proteins,
which does not require macroscopically ordered samples, is
magic angle sample spinning (MAS) NMR in combination
with residue-speciﬁc labelling. For example, a number of
NMR studies have used residue-speciﬁc 13C labelling in the
protein backbone which revealed information on conforma-
tion and dynamics that are directly related to the protein
function in the membrane [21]. Careful application of such
labelling schemes can yield structural information from pro-
teins as large as 60 kDa [22]. Recently, uniform 13C/15N la-
belling schemes for MAS-NMR have been demonstrated to
provide a number of structural constraints in microcrystalline
samples of SH3, which oﬀers a potential approach for smaller
membrane proteins [23]. MAS-NMR can also be used to study
ligands bound to membrane proteins as demonstrated in the
structure determination of neurotensin bound to the neuro-
tensin receptor [24]. Magic angle oriented sample spinning
(MAOSS) (a combination of alignment techniques and MAS-
NMR) on speciﬁcally 15N-labelled bacteriorhodopsin has been
used to measure the orientations of trans-membrane helical
residues [25].
These examples demonstrate that a variety of tools are
available to study membrane embedded proteins, such as ABC
transporters, by solid-state NMR. However, no applications to
ABC transporters have been reported so far and all applica-
tions to secondary transporters were restricted to the obser-
vation of bound substrate by either using naturally abundant
31P [26] or synthetically 13C/2H enriched [27–31] ligands.
A number of bottlenecks have to be addressed before solid-
state NMR experiments on ABC transporters like LmrA can
be performed successfully. Established expression systems have
to be optimised so that large quantities (mg) of isotope labelled
protein can be obtained. Eﬃcient solubilisation and puriﬁca-
tion procedures must be established. Particular attention needs
to be paid to reconstitution of puriﬁed transporter back intomembranes at concentrations high enough to make an NMR
experiment feasible (lipids/proteins < 1000 mol/mol). Further-
more, a functional assay should be used to monitor the activity
of the reconstituted protein.
Examples of multi-domain membrane proteins that can be
heterologously expressed at levels suitable for structural
studies are rare and examples where such proteins have been
labelled for NMR purposes are even more limited [32,33]. Cell
free synthesis has recently been applied successfully to mem-
brane proteins [34] but may not be capable of producing such
large systems in a correctly folded and functional state. For
this reason, we have sought to take advantage of the ability to
produce large amounts of functional LmrA in L. lactis. Am-
pliﬁed expression in L. lactis oﬀers a number of advantages.
The cells grow rapidly to a high cell density and over-expressed
membrane proteins are found exclusively within the cytoplas-
mic membrane and not in inclusion bodies. Proteins can then
be solubilised directly from the membrane by mild detergents,
while puriﬁcation is simpliﬁed by the small genome size.
Here, we demonstrate the use of this homologous expression
system to produce quantities of selectively [13C]glycine-labelled
LmrA (ca. 1 mg LmrA/l culture), puriﬁed and reconstituted
into lipid vesicles in an active form and in suﬃcient quantities
for solid-state NMR experiments. Successfully reconstituted
protein in proteoliposomes was separated from protein free
liposomes and protein aggregates, and the ﬁrst solid-state
NMR spectra were recorded. Our data demonstrate the suit-
ability of this expression system for further studies of LmrA
structure and function by NMR.2. Materials and methods
2.1. Materials
Difco Laboratories’ M-17 medium was obtained from BD, Sparks,
MD; n-dodecyl-b-D-maltoside (DDM) from Glycon Biochemicals
GmbH, Luckenwalde, Germany; Ni2þ nitriloacetic acid (NI–NTA)
resin from Qiagen, Inc.; Bio-beads, SM-2 from Bio-Rad Laboratories
Inc; E. coli lipids from Avanti Polar lipids, Alabaster, AL. [13C1]gly-
cine was obtained from Campro Scientiﬁc GmbH, distributors for
Isotec, Miamisburg, OH. All other reagents were of analytical grade or
better.
2.2. Bacterial strains and growth conditions
Lactococcus lactis strain NZ9000 was used as a host for the ex-
pression vector pNHLmrA [35], whilst NZ9700 was used as a nisin
producing strain. Cells were cultured overnight at 30 C in M-17 me-
dium or deﬁned medium, both supplemented with 0.5% (w/v) glucose
and 5 lg/ml chloramphenicol, and used to start large scale cultures (2 l)
grown at 30 without shaking and in the dark. LmrA expression was
induced at an OD660 of 1.0 (1 cm path length) through the addition of
1 ml (per litre culture) of the supernatant acquired during harvesting of
NZ9700 cells by centrifugation. The deﬁned medium was adapted from
a previously published recipe [36] and contained, per litre double dis-
tilled water; L-alanine 0.3 g, L-arginine HCl 0.36 g, L-asparagine 0.48
g, L-aspartic acid 0.04 g, L-cysteine HCl 0.12 g, L-glutamic acid 0.48 g,
L-glutamine 0.48 g, glycine 0.12 g, L-histidine 0.12 g, L-isoleucine 0.36
g, L-lysine HCl 0.72 g, L-methionine 0.20 g, L-phenylalanine 0.36 g, L-
proline 0.60 g, L-serine 0.36 g, L-threonine 0.36 g, L-tryptophan 0.09 g,
L-tyrosine 0.24 g, L-valine 0.60 g, NH4Cl 3.75 g, KH2PO4 2.5 g,
K2HPO4 3.25 g, MgSO4.7H2O 0.87 g, NaCl 0.53 g, thiamine HCl 0.1
mg, riboﬂavin 1 mg, niacin 1 mg, pyridoxal-HCl 2.3 mg, p-amino-
benzoic acid 0.1 mg, folic acid 1 mg, D-biotin 0.1 mg and trace
amounts of adenine, guanine and uracil. The ﬁnal pH was between 6
and 6.5.
2.3. Sample preparation
Inside out vesicles (ISOV) were prepared and histidine tagged
LmrA was puriﬁed as described previously [35] with the following
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used in place of potassium phosphate buﬀer throughout. During de-
tergent solubilisation of LmrA containing ISOVs, the ﬁnal concen-
tration of DDM was 3% (w/v). Solubilised protein was incubated with
10 g of Ni–NTA resin and loaded on a column (Pharmacia) attached
to an €AKTA prime FPLC. Unbound protein was removed from the
column using previously described buﬀers [35] and, when no further
protein was detected in the ﬂow (OD monitored at 280 nm), LmrA was
eluted with buﬀer at pH 7.0 containing 250 mM imidazole. Washed
biobeads were pre-incubated in a suspension of E. coli lipids to reduce
removal of lipids from solution during the reconstitution process [37].
Lipids at a starting molar ratio of 200 lipids per protein were sus-
pended in 50 mM Tris, 25 mMKCl, and 10 mM EDTA buﬀer at pH 7.
The lipid suspension was sonicated brieﬂy in a bath sonicator and then
extruded (Northern Lipid Extruder) 11 times through a 400 nm ﬁlter
(Whatman, Maidstone, UK). The liposome suspension was then ti-
trated with a 0.02 M DDM solution as described [35] and mixed with
detergent solubilised LmrA that had been concentrated (Centricon
YM-50, average RCF 655g, 20 min; 4 C). The detergent destabilised
liposomes and puriﬁed protein were incubated for 30 min at room
temperature before biobeads (ﬁnal concentration of 80 mg/ml) were
added. The mixture was incubated for a further 30 min at room
temperature and then overnight at 4 C. After removal of biobeads, the
(proteo)liposomes were pelleted by centrifugation (average RCF
190 000 g; 30 min; 4 C). Reconstituted protein in proteoliposomes
was separated from liposomes and protein aggregates by sucrose
density centrifugation. The reconstituted complexes were resuspended
and layered over a discontinuous sucrose gradient (10–20–30%) (av-
erage RCF 83 000 g; 18 h; 4 C). Bands were collected from the su-
crose gradient and washed with 50 mM Tris, 25 mM KCl, and 10 mM
EDTA buﬀer at pH 7 before being pelleted as before and loaded into 4
mm MAS rotors (Bruker GmbH, Kahlsruhe, Germany). Protein
concentrations were measured using the Bio-Rad DC protein assay kit
as adapted from Lowry et al. [38].
2.4. Enzyme assay
The ATPase assay of reconstituted LmrA was based on a colori-
metric ascorbic acid/ammonium molybdate assay [39] to measure the
liberation of Pi from ATP. 50 mM ATP and 10 mMNa orthovanadate
stock solutions were freshly prepared. Reconstituted LmrA was wa-
shed twice with 20 mM K–HEPES (pH 7.0), 5 mM MgSO4 buﬀer and
resuspended at a ﬁnal concentration of 2.5 mg/ml. ATPase assays were
performed at 30 C in a reaction volume of 20 ll. Following incubation
of reconstituted LmrA and ATP (ﬁnal concentration 5 mM) for
10 min, the ATPase reactions were terminated by addition of 40 ll of a
freshly prepared acidic solution consisting of 0.48% (w/w) ammonium
heptamolybdate tetrahydrate, 6.6% (v/v) concentrated sulfuric acid,
0.01% (w/w) potassium antimonyl tartrate and 0.42% (w/w) ascorbic
acid. Following the addition of 140 ll H2O and 30 min of incubation
at 30 C in the dark, the absorbance was measured at 690 nm. ATPase
activity measurements in the presence of 1 mM orthovanadate were
obtained in parallel and subtracted from the readings.
2.5. Electron microscopy
For freeze-fracturing reconstituted membrane vesicles in suspension
placed between two small copper blades were frozen by plunging into
ethane cooled to )180 C by liquid nitrogen. Samples were fractured in
a freeze-fracture unit (400T from Balzers, Lichtenstein) and shadowed
with platinum/carbon at an angle of 45. Replicas reinforced by pure
carbon shadowing at an angle of 90 were cleaned from organic ma-
terial in chromo-sulfuric acid and later-on analysed by electron mi-
croscopy (EM208S, Philips, Eindhoven, The Netherlands).
2.6. Solid-state NMR
All experiments were performed on a Bruker Avance 600 equipped
with a 4 mm MAS DVT probe. Cross polarisation (CP) experiments
were performed at 150.9 MHz for 13C employing a 80–100% ramped
proton pulse of 1.5 ms to satisfy the Hartmann–Hahn condition. Two
pulse phase modulated (TPPM15) heteronuclear 1H decoupling at a
ﬁeld of 62.5 kHz and a 49 ms acquisition time with a recycle delay of 2
s was used. Spectra were zero ﬁlled to 16k points and 50 Hz (13C)
exponential line broadening was applied during processing. Spectra
were referenced externally to the carbonyl resonance of glycine at
176.03 ppm. All experiments were carried out at temperatures of 233
and 253 K.3. Results and discussion
Growth of L. lactis on the chemically deﬁned medium is
comparable with that on M17 medium in terms of growth rate
but with a reduced ﬁnal cell density of 50%. This reduced
growth is reﬂected in the ﬁnal yield of puriﬁed LmrA. Here, we
have typically puriﬁed 2 mg of LmrA per litre of M17 medium
compared with 1 mg LmrA per litre of deﬁned medium. The
total protein yield in ISOVs was approximately 3 mg/l deﬁned
medium.
The incorporation of 13CO-glycine demonstrates that L.
lactis is able to grow and express LmrA suﬃciently well, so
that the high levels of protein required for solid-state NMR
experiments can be obtained. Although LmrA is expressed at
up to 30% of total membrane protein, spectra directly obtained
from ISOVs prepared from L. lactis are not suitable for further
NMR studies since signal from labelled LmrA cannot be dis-
cerned from other membrane constituents.
Therefore, we have sought to solubilise labelled LmrA, pu-
rify using established techniques and then reconstitute into a
lipid environment at a high protein density. Detergent solu-
bilised LmrA, eluted from the Ni–NTA column, was used
immediately for reconstitution. As reported previously [35], a
protein purity of 97% as judged by densitometric analysis of
SDS–PAGE gels was achieved.
Existing protocols [35] combine LmrA and lipids at a ratio
of 1/100 (w/w), which would allow approximately 0.1 mg of
this 64 kDa protein to be ﬁtted into the 20–80 ll internal
volume of the standard MAS rotors with 4 mm diameter used
for NMR experiments. Current solid-state NMR techniques
are insuﬃciently sensitive to this amount of labelled protein
and good quality spectra cannot be obtained. Therefore, we
reconstituted LmrA in lipids at a ratio of between 1/1 and 1/10
(w/w) providing between approximately 100 and 1000 lipids
per LmrA monomer and allow between 0.5 and 5 mg of la-
belled LmrA to be introduced into a MAS rotor per NMR
experiment. The resulting protein–lipid vesicles were collected
by centrifugation. The presence of LmrA associated with the
vesicles was conﬁrmed by SDS–PAGE gel analysis and by 13C
CPMAS NMR of 13CO glycine labelled LmrA (data not
shown).
A functional assay detecting ATP turnover conﬁrmed the
activity of the LmrA NBD for reconstituted LmrA using our
method (Fig. 1). Reconstitution by co-dissolving protein and
lipids in detergent solution after which the detergent was re-
moved by incubation in the presence of biobeads has been
tested as well but produced reconstituted complexes for LmrA
with very poor ATPase activity (data not shown). The vana-
date sensitive ATPase activity of the sample reconstituted by
the detergent destabilisation method was determined to be 47
nmol/min/mg protein (Fig. 1), which can be compared with
reported activity of about 150 nmol/min/mg for LmrA in
ISOVs [2] and conﬁrms the suitability of this reconstitution
approach. The ATPase activity in our reconstituted system
may be an underestimation of the total activity, since many
ATP-binding sites may be located in the vesicle lumen and are
not accessible to ATP.
Analysis of proteoliposome suspension directly after recon-
stitution by freeze fracture electron microscopy revealed the
presence of proteoliposomes, both protein free liposomes and
LmrA aggregates. Initially, the protein aggregates could not be
separated from the successfully reconstituted protein using




















Fig. 1. The colorimetric ATPase assay performed on functionally re-
constituted LmrA (in proteoliposomes) compares inorganic phosphate
turnover with increasing amounts of LmrA over 10 min.
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the reconstitution buﬀer led to three well resolved bands on the
gradient. The three bands were collected and analysed by
freeze fracture electron microscopy and 13C CPMAS NMR
(Fig. 2). The lowest density band (9% sucrose) contained only
protein free liposomes. The spectrum of this band was char-
acterised by natural abundance signals from lipids and a lack
of any intense signal in the carbonyl region from 13CO glycine
labelled LmrA (Fig. 2(a)). In the spectrum of the second bandFig. 2. 13C CPMAS spectra of three fractions of a sucrose density
centrifugation of LmrA functionally reconstituted in proteoliposomes
prepared using E. coli lipids: (a) 9% sucrose: protein free liposomes, (b)
17% sucrose: proteoliposomes containing 13CO glycine labelled LmrA,
(c) 28% sucrose: protein aggregates. Spectra recorded at 8 kHz MAS
spinning frequency and 253 K. 62k (b) and 56k (a, c) transients were
acquired for each spectrum and 62.5 kHz TPPM heteronuclear 1H
decoupling was applied during acquisition. The corresponding freeze
fracture electron micrographs are shown at 10k, 16k and 20k magni-
ﬁcation for (a), (b) and (c), respectively.(17% sucrose) (Fig. 2(b)), an increased peak intensity at 172.4
ppm indicated the presence of 13CO glycine labelled LmrA.
The corresponding electron micrographs for the second band
showed well-formed lipid vesicles with protein incorporated
and no evidence of aggregated protein (Fig. 2(b)). The aggre-
gated protein was found to accumulate almost exclusively in
the densest band (28% sucrose) (Fig. 2(c)). The 13C CPMAS
spectrum of this sample was characterised by low signal in-
tensity and was composed largely of signal from aggregated
protein (175.8 ppm) with some associated lipids.
The ﬁnal lipid/protein ratio of our successfully reconstituted
samples was estimated from the CP-MAS-NMR intensities of
lipid and protein resonances and yielded approximately 1:3 (w/
w) corresponding to ca. 250 lipids per protein monomer.
In the sucrose density centrifugation technique, the suc-
cessfully reconstituted LmrA was separated from liposomes
and protein aggregates to assess their individual contributions
to the CPMAS spectrum of reconstituted LmrA. Unfortu-
nately, the colorimetric ATPase assay showed negligible AT-
Pase activity after this ﬁnal puriﬁcation stage (data not
shown). This is probably due to the long time taken for the
sucrose gradient and subsequent washing steps. However, the
ratio of aggregated to lipid-reconstituted LmrA is estimated to
be less than 1:9 as judged from the intensity of the observed
NMR protein resonances, indicating that aggregated protein
did not contribute dramatically to the observed signal.
Therefore, the ﬁnal sucrose density centrifugation stage can be
omitted in future experiments in order to study LmrA in a
functional form. Although LmrA is stable at 4 C after re-
constitution, all further steps such as storage or NMR exper-
iments were carried out at low temperatures (233–253 K) to
ensure long term stability. In our optimised protocol, the ﬁnal
reconstituted sample contained up to 3 mg labelled LmrA,
which is compatible with a standard MAS-NMR rotor, and
provided suﬃcient sensitivity to produce good signal to noise
spectra within a realistic time frame.
Application of the preparatory techniques described here
together with alternative 13C labelling schemes using less
abundant residues with larger chemical shift dispersion will
give access to a range of solid-state NMR experiments to
probe the environment of theses residues. Information about
backbone conformation and dynamics of LmrA are now ac-
cessible in a non-perturbing, site-directed manner and will
advance NMR analysis on this member of the ABC trans-
porter superfamily.
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